AM

Amicogen, Inc.

Industrial biotechnology company specializing in specialty enzymes and proteins.

092040 | KO

Overview

Corporate Details

ISIN(s):
KR7092040005
LEI:
Country:
South Korea
Address:
경상남도 진주시 문산읍 월아산로950번길 14-10 아미코젠 문산 1공장, 진주시

Description

Amicogen, Inc. is an industrial biotechnology company specializing in the development and production of specialty enzymes and proteins. The company operates across three primary business areas: Enzyme and Biopharmaceuticals, Healthcare and Nutrition, and Bioprocess and CDMO (Contract Development and Manufacturing Organization) services. Leveraging its proprietary enzyme technology, Amicogen creates innovative solutions for the biopharmaceutical, food, and cosmetics industries. The healthcare division develops and manufactures functional food ingredients and nutritional products. The company also provides bioprocess solutions, including protein purification resins and comprehensive CDMO services to support the biopharmaceutical sector.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-24 00:00
주식등의대량보유상황보고서(일반)
Korean 94.9 KB
2025-01-23 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 8.6 KB
2025-01-22 00:00
주식등의대량보유상황보고서(일반)
Korean 98.1 KB
2025-01-20 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 8.6 KB
2025-01-14 00:00
[기재정정]주주총회소집결의
Korean 13.3 KB
2025-01-10 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양도결정)
Korean 21.4 KB
2025-01-08 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.6 KB
2025-01-08 00:00
주주총회소집결의
Korean 10.1 KB
2025-01-08 00:00
[기재정정]주주총회소집결의
Korean 13.2 KB
2025-01-03 00:00
주식등의대량보유상황보고서(일반)
Korean 104.1 KB
2025-01-02 00:00
합병등종료보고서(합병)
Korean 18.9 KB
2024-12-26 00:00
[기재정정]주요사항보고서(타법인주식및출자증권양도결정)
Korean 21.4 KB
2024-12-23 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 8.7 KB
2024-12-23 00:00
불성실공시법인미지정 (지정유예)
Korean 5.5 KB
2024-12-16 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB

Automate Your Workflow. Get a real-time feed of all Amicogen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amicogen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amicogen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.